TUE, DEC 22, 2020 16:30 CET Cereno Scientific announced today that the agreement with Mangold Fondkommission to act as liquidity provider for the company’s share has been terminated. The share…
Read More
FRI, OCT 02, 2020 17:41 CET As previously announced, the Board of Directors of Cereno Scientific AB (”Cereno” or the ”Company”) has decided to distribute warrants of series TO1 and…
THU, NOV 19, 2020 08:33 CET The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for the third quarter 2020. Summary of the interim report Cereno Scientific Group Year…
TUE, SEP 29, 2020 17:30 CET Cereno Scientific today announced that the company will advance the development of drug candidate CS1 as an epigenetic modulator of rare diseases with orphan…
TUE, JUN 09, 2020 08:40 CET Cereno Scientific today announced that the company enters a collaboration agreement with the University of Michigan in Ann Arbor, USA. On behalf of Cereno…
The Board and Chief Executive Officer of Cereno Scientific AB here with present the Interim Report for the first quarter 2020. Summary of the Interim Report Cereno Scientific Group (2020-01-01…
Cereno Scientific develops innovative medicines for cardiovascular and rare diseases related to fibrosis, thrombosis, inflammation and high blood pressure in the lung as well as systemically. As a step towards…
Cereno Scientific develops innovative drugs for cardiovascular diseases, with a broadened focus on thrombosis and rare fibrosis-related cardiovascular diseases. Recently, the company’s lead candidate CS1 received Orphan Drug Designation from the FDA for the…
Cereno Scientific is accelerating the building of a platform of drug candidates in epigenetic modulation, by HDAC inhibition, for cardiovascular and rare diseases. On March 10, the company’s main candidate…
